Φορτώνει......
Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: a CIBMTR Analysis
Gemtuzumab ozogamicin (GO) therapy prior to allogeneic hematopoietic cell transplantation (alloHCT) has been historically associated with an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with acute myeloid leukemia (AML). The current analysis...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Biol Blood Marrow Transplant |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7439134/ https://ncbi.nlm.nih.gov/pubmed/31891815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.12.763 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|